Market Cap 407.20M
Revenue (ttm) 10.12M
Net Income (ttm) -220.66M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2,180.43%
Debt to Equity Ratio 0.00
Volume 4,110,083
Avg Vol 4,059,766
Day's Range N/A - N/A
Shares Out 266.14M
Stochastic %K 10%
Beta 1.84
Analysts Strong Sell
Price Target $9.59

Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in United Kingdom and internationally. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 20 3829 6230
Address:
The Mediaworks, 191 Wood Lane White City, London, United Kingdom
XX1XX
XX1XX Oct. 27 at 3:59 PM
$AUTL the BlueBird hangover is real. Scam St is saying having a cure is not enough in this space due to the complexity of the procedure and terrible COGS numbers. Once again we are back to show me the money as not even a legit cure for Lupus is moving the stock.
1 · Reply
Michael_garic
Michael_garic Oct. 27 at 3:39 PM
$AUTL a lot of chunk buying on the exchange today and not much selling... mainly shorts selling in small bits trying their best to kill the rally
0 · Reply
wussel
wussel Oct. 27 at 3:34 PM
$AUTL What's up? Did investors finally wake up?
0 · Reply
keypatience
keypatience Oct. 27 at 3:33 PM
0 · Reply
MedHS55
MedHS55 Oct. 27 at 3:29 PM
$AUTL I guess somebody woke up and realizes this was good news..
1 · Reply
GeniusLoci
GeniusLoci Oct. 27 at 2:57 PM
$AUTL Remarkable safety and efficacy lupus data. A BP head-turner
0 · Reply
wussel
wussel Oct. 27 at 2:51 PM
$AUTL I think the next step to watch is how fast they can recruit patients for phase 2. One would think that if the results of phase 1 spread among affected patients, the recruiting should be finished quite fast.
0 · Reply
alexpitti
alexpitti Oct. 27 at 2:35 PM
I guess I was right. Friday was the last day to buy Autolus before the data. However, investors don't care about the great data like many predicted. $AUTL
0 · Reply
keypatience
keypatience Oct. 27 at 2:34 PM
$AUTL Yes but very small sample size: n=6 limits generalizability and Median follow-up 8.9 months limits long-term durability evidence
1 · Reply
QHD
QHD Oct. 27 at 2:28 PM
$AUTL This is incredible news! 83% remission in Lupus!!! 50% had Kidney Restoration! Obe-cel is showing to be a wonder-drug!
0 · Reply
Latest News on AUTL
Autolus Therapeutics plc (AUTL) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 4:37 PM EDT - 2 months ago

Autolus Therapeutics plc (AUTL) Q2 2025 Earnings Call Transcript


Autolus Therapeutics plc (AUTL) Q1 2025 Earnings Call Transcript

May 11, 2025, 4:22 AM EDT - 6 months ago

Autolus Therapeutics plc (AUTL) Q1 2025 Earnings Call Transcript


Autolus Announces Pricing of Underwritten Offering

Feb 8, 2024, 7:00 AM EST - 1 year ago

Autolus Announces Pricing of Underwritten Offering


Autolus Upgrades Leadership And Faces CAR-T Approval

Feb 6, 2024, 9:52 AM EST - 1 year ago

Autolus Upgrades Leadership And Faces CAR-T Approval


XX1XX
XX1XX Oct. 27 at 3:59 PM
$AUTL the BlueBird hangover is real. Scam St is saying having a cure is not enough in this space due to the complexity of the procedure and terrible COGS numbers. Once again we are back to show me the money as not even a legit cure for Lupus is moving the stock.
1 · Reply
Michael_garic
Michael_garic Oct. 27 at 3:39 PM
$AUTL a lot of chunk buying on the exchange today and not much selling... mainly shorts selling in small bits trying their best to kill the rally
0 · Reply
wussel
wussel Oct. 27 at 3:34 PM
$AUTL What's up? Did investors finally wake up?
0 · Reply
keypatience
keypatience Oct. 27 at 3:33 PM
0 · Reply
MedHS55
MedHS55 Oct. 27 at 3:29 PM
$AUTL I guess somebody woke up and realizes this was good news..
1 · Reply
GeniusLoci
GeniusLoci Oct. 27 at 2:57 PM
$AUTL Remarkable safety and efficacy lupus data. A BP head-turner
0 · Reply
wussel
wussel Oct. 27 at 2:51 PM
$AUTL I think the next step to watch is how fast they can recruit patients for phase 2. One would think that if the results of phase 1 spread among affected patients, the recruiting should be finished quite fast.
0 · Reply
alexpitti
alexpitti Oct. 27 at 2:35 PM
I guess I was right. Friday was the last day to buy Autolus before the data. However, investors don't care about the great data like many predicted. $AUTL
0 · Reply
keypatience
keypatience Oct. 27 at 2:34 PM
$AUTL Yes but very small sample size: n=6 limits generalizability and Median follow-up 8.9 months limits long-term durability evidence
1 · Reply
QHD
QHD Oct. 27 at 2:28 PM
$AUTL This is incredible news! 83% remission in Lupus!!! 50% had Kidney Restoration! Obe-cel is showing to be a wonder-drug!
0 · Reply
TricksterT
TricksterT Oct. 27 at 1:59 PM
0 · Reply
wussel
wussel Oct. 27 at 1:58 PM
$AUTL The presentation tomorrow is supposed to last two hours, so jut reading the information from today's PR will not be enough to fill these two hours. I am looking forward to the actual presentaion material which will hopefully be availble online
1 · Reply
XX1XX
XX1XX Oct. 27 at 1:55 PM
$SNDX learn from $AUTL - now that you have FDA approval expect a new 52week low. This is the new Scam St. playbook. COGS and Revenue will be the only thing that matters.
1 · Reply
XX1XX
XX1XX Oct. 27 at 1:15 PM
$AUTL what chatgpt thinks about the news: Rating: 9/10 The release is highly positive and data-rich, clearly demonstrating both safety and efficacy in a small but meaningful cohort. It effectively positions obe-cel as a breakthrough candidate in lupus treatment.
0 · Reply
XX1XX
XX1XX Oct. 27 at 1:14 PM
$AUTL wow. another great news release and nobody cares. wtf is up with this stock.
1 · Reply
Michael_garic
Michael_garic Oct. 27 at 11:52 AM
$AUTL increased short interest makes no sense???
2 · Reply
JcoalX
JcoalX Oct. 27 at 11:42 AM
$AUTL premarket pump, followed by some dude that dumps his shares…… let’s break this cycle!
1 · Reply
wussel
wussel Oct. 27 at 11:09 AM
$AUTL Short interest increased by appr. 400,000 to 11,8 million shares, hopefully this time short sellers can not cover cheaply like they did last time thanks to brainless Wellington selling https://www.nasdaq.com/market-activity/stocks/autl/short-interest
1 · Reply
RonIsWrong
RonIsWrong Oct. 27 at 11:06 AM
$AUTL Autolus Therapeutics Presents Clinical Data Updates at the American College of Rheumatology Convergence 2025 Data from the Phase 1 CARLYSLE study in severe refractory systemic lupus erythematosus (srSLE) suggests obe-cel is well tolerated with no ICANS or high-grade CRS; 50 million cell dose selected for Phase 2 pivotal study Preliminary efficacy data demonstrate achievement of definition of remission in SLE (DORIS) in 83% of patients and complete renal response (CRR) in 50% of patients; all responses and remissions are ongoing with no evidence of disease activity at a median follow-up of 8.9 months All patients had refractory lupus nephritis; 4/6 patients had significantly impaired kidney function Patients received no other lupus directed therapy; steroids were tapered in all patients to 5mg by month six Company remains on track to dose first patient in Phase 2 trial in lupus nephritis (LN) by year-end 2025
0 · Reply
keypatience
keypatience Oct. 27 at 9:11 AM
$AUTL Autolus Therapeutics will present updated clinical data from its Phase I CARLYSLE study (obecabtagene autoleucel, or obe-cel) for severe refractory systemic lupus erythematosus on Tuesday, October 28, 2025.
0 · Reply
MobyDick2324
MobyDick2324 Oct. 27 at 4:42 AM
$AUTL big week guys…
1 · Reply
Flying_Trader2
Flying_Trader2 Oct. 27 at 3:31 AM
$AUTL I wonder if the RNA Novartis deal will have any affect on AUTL, scientifically they are in the same neck of the woods, no?
1 · Reply